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Abstract: Somatostatin (SST) analogues are used to control the proliferation and symptoms of
neuroendocrine tumors (NETs). MicroRNAs (miRNA) are small non-coding RNAs that modulate
posttranscriptional gene expression. We wanted to characterize the miRNAs operating under the
control of SST to elucidate to what extent they mediate STT actions. NCI-H727 carcinoid cell line was
treated with either a chimeric SST/dopamine analogue; a SST or dopamine analogue for proliferation
assays and for identifying differentially expressed miRNAs using miRNA microarray. The miRNAs
induced by SST analogue treatment are investigated in carcinoid cell lines NCI-H727 and CNDT2
using in situ hybridization, qPCR and proliferation assays. SST analogues inhibited the growth of
carcinoid cells more potently compared to the dopamine analogue. Principal Component Analysis
(PCA) of the samples based on miRNA expression clearly separated the samples based on treatment.
Two miRNAs which were highly induced by SST analogues, miR-7 and miR-148a, were shown to
inhibit the proliferation of NCI-H727 and CNDT2 cells. SST analogues also produced a general
up-regulation of the let-7 family members. SST analogues control and induce distinct miRNA
expression patterns among which miR-7 and miR-148a both have growth inhibitory properties.
Keywords: somatostatin analogues; neuroendocrine tumors; cancer; miRNAs; miR-148a; miR-7; let-7
1. Introduction
Gastro-Entero-Pancreatic neuroendocrine neoplasms (GEP-NEN) are generally slow growing
tumors originating from neuroendocrine cells in the gastro-intestinal tract, the diffuse neuroendocrine
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system, pancreas and the bronco-pulmonary system [1]. According to the World Health Organization
(WHO) 2010 classification [2] GEP-NEN can be classified according to Ki67 index and/or mitotic
count into neuroendocrine tumors (NETs, NET-G1 and NET-G2) and neuroendocrine carcinomas
(NEC G3) [2,3]. The bronco-pulmonary NENs are classified according to mitoses pr. 2 mm2 and the
presence or absence of necrosis according to the 2015 WHO classification [4]. This separates small-cell
and large-cell, poorly differentiated based on mitosis only, and the typical carcinoids (TCs) and atypical
carcinoids (ACs) by <2 mitoses per 2 mm2/no necrosis and 2–10 mitoses per 2 mm2/with focal necrosis.
In general, NETs of the lung comprise <20% of all lung cancers, and TCs and ACs comprise 1–2%
of these [4,5]. The yearly incidence of GEP-NENs and bronco-pulmonary NENs is 2–3 and 0.2–2
per 1,000,000 inhabitants respectively, but this has been increasing during the last decades [1,6–8].
TCs share homologies with G1 GEP-NENs and ACs with G2 GEP-NENS coinciding with the fact that
ACs are more malignant in nature and more prone to metastasize compared to TCs [8,9]. The clinical
picture depends on the site of the primary tumor and its ability to secrete neuroamines and/or
peptides at supra-physiological levels (functioning tumors) as the clinical syndrome depends on the
transmitter/hormone secreted [10]. However, most of the GEP-NENs and bronco-pulmonary NENs
are silent or ‘non- functional’, as they either do not secrete any transmitters/hormones or the one they
secrete does not cause clinical symptoms [10,11]. The lack of endocrine symptoms in these patients
often delays the diagnosis until the presence of symptoms caused by the mass effect and/or the
presence of metastases, mainly hepatic metastases [12]. In patients with localized low grade GEP-NETs,
the 5- year survival rate is 60–100% whereas patients with regional disease or distant metastases have
40% and 29% 5-year survival rates respectively [13]. In bronco-pulmonary NENs the overall survival
is higher in TCs versus ACs with a 5-year survival rate of 90% and 60% respectively and increases with
resectable tumors [14].
A common feature for endocrine cells is that both their secretion and growth can be inhibited by
somatostatin (SST) [15]. In the nervous tissue, SST acts like a neurotransmitter and a neuromodulator.
In the gastrointestinal tract, SST is expressed by specialized endocrine cells and acts as a paracrine
factor [16]. The somatostatin receptors (SSTRs) belong to the G-protein coupled receptor family
and there are five different SSTR subtypes (SSTR1-5), all differently expressed by neuroendocrine
cells [17]. Seventy to ninety percent of all GEP-NET express SSTRs and tumors expressing SSTRs
often contain one or more receptor subtypes, most often SSTR1, 2, 3 and 5, whereas SSTR4 is less
commonly seen in endocrine tumors [18]. This has made SST useful for both visualization and
treatment [19,20]. The expression is also related to the tumor grade, since the receptors are preferably
expressed in low grade tumors, whereas the expression of some receptor subtypes is reduced in the
more dedifferentiated tumors [21]. The different SSTR subtypes all bind the endogenous ligands;
SST14, SST 28 and cortistatin; with equally high affinity in the nanomolar (nM) range. The widespread
expression of SSTRs by a large number of human tumors and the biological actions of SSTRs form
the basis for in vivo tumor targeting. However, the short half-life in circulation (1–3 min) of the
endogenous SST peptides makes them unsuited for therapy [22]. Therefore a number of synthetic
analogues with longer half-lives, such as somatostatin SMS201-995 (Octreotide), RC-160 (Vapreotide),
BIM-23014 (Lanreotide), MK678 (Seglitide) and SOM-230 (Pasireotide LAR), were developed and
are currently in clinical use [23,24]. Surgical removal is the optimal treatment for GEP-NENs and
bronco-pulmonary NENs, and somatostatin analogue (SSA) treatment constitutes the gold standard
for symptomatic and anti-proliferative control [8,25].
MicroRNAs (miRNAs) are small non-coding RNA molecules (on average 20–23 nucleotide (nt)
long) that modulate gene expression by binding to complementary sequences on target messenger RNA
(mRNAs). This predominantly results in a decrease of target mRNA levels [26]. An increasing number
of studies indicate that miRNAs are involved in many important biological processes, including
proliferation, apoptosis, differentiation, angiogenesis and immune response. miRNA deregulation
leads to aberrant gene expression in various diseases and dysregulation of miRNA expression have
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been shown to be involved in cancer development [27]. We therefore wanted to examine which miRNA
operate under the control of SST and if they contribute to the growth- inhibitory effects of SST.
2. Materials and Methods
2.1. Cell Lines and Tissue Culture
Four human carcinoid cell lines, two intestinal (CNDT2 and HC45) and two of pulmonary origin
(NCI-H720 and NCI-H727) were used for experiments.
CNDT2 is a human midgut carcinoid cell line kindly provided by Lee M. Ellis M.D. Anderson
Center Texas USA [28] and grown in DMEM/F12 with 15 mM HEPES (Life Technologies,
Carlsbad, CA, USA) supplemented with 10% FBS (Th. Geyer GmbH, Stuttgart, Germany), penicillin
100 U/mL and streptomycin 100 µg/mL (Life Technologies), 5 mL Sodium pyruvate 100 mM
(Sigma-Aldrich, St. Louis, MO, USA), 5 mL MEM NEAA 100x (Life Technologies), 5 mL L-Glutamine
200 mM 100x (Life) and 10 ng/mL NGF (Life Technologies) and kept at 37 ◦C/5% CO2. HC45 is a
human ileal carcinoid cell line kindly provided by Ricardo V. Lloyd Mayo Clinic [29] and kept in RPMI
1640/Glutamax (GIBCO, Waltham, MA, USA) supplemented with 10% FBS, 1% P/S and 10 ng/mL
Insulin (Invitrogen, Carlsbad, CA, USA) at 37 ◦C and 5% CO2.
NCI-H720 is an atypical and NCI-H727 is a typical human pulmonary carcinoid cell line
obtained from ATCC (Boras, Sweden). Both cell lines were cultured in RPMI 1640 Glutamax
supplemented with 10% FBS, penicillin 100 U/mL and streptomycin 100 µg/mL, 1 mM Sodium
Pyruvate (Life Technologies) at 37 ◦C and 5% CO2.
For experiments involving seeding cells into new plates, cells were always allowed to
adhere overnight.
2.2. Tumor Tissue
Five formalin-fixed and paraffin-embedded (FFPE) tissue samples of carcinoid tumors (see Table 1),
obtained from the Department of Pathology (Rigshospitalet, Copenhagen, Denmark), were used
for Laser Capture Microdissection, qPCR and in situ hybridization, see descriptions for the
procedures below.
Table 1. Tissue used for immunohistochemistry, in situ hybridization and qPCR.
Patient Age/Sex Location Ki67 Index Treatment
1 65/F Colon 1% Surgery
2 69/F Small intestine 3% Surgery/SSA
3 62/M Ileum 2% Surgery
4 55/F Small intestine 7–8% Surgery
5 64/F Ileocecal 1% Surgery/SSA
2.3. Somatostatin Analogues
Two SST analogues (BIM-23014 (Lanreotide) and BIM-23023), a combined SST-dopamine 2
receptor analogue (BIM-23A760) and a pure dopamine receptor D2 (DRD2) analogue (BIM-53097) were
used. The compounds’ binding affinities for the SST and dopamine receptors are shown in (Table 2).
The compounds were initially dissolved in 100 µL 99% EtOH then in 0.1 N acetic acid/0.1% BSA to a
final stock concentration of 10−3 M and used for experiments at suitable concentrations in complete
growth medium.
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Table 2. Human Somatostatin Receptor Subtype Specificity (IC50-nM) [30,31].
Compound Somatostatin Receptor Subtype Dopamine
1 2 3 4 5
Somatostatin 14 1.95 0.25 1.2 1.77 1.4
Somatostatin 28 1.86 0.31 1.3 5.4 0.4
BIM-23014 (Lanreotide) >1000 0.75 98 >1000 12.7
BIM-23023 >1000 0.42 87 2.7 4.2
BIM-53097 22.1
BIM-23A760 622 0.03 160 >1000 42.0 15
2.4. Transfection Studies and Cell Growth Analyses
A total of 4 × 106 NCI-H727 or 1.5 × 106 CNDT2 cells were seeded and used for each transfection.
To 965 µL Opti-MEM (Invitrogen) 10 µL Negative control 1 or 2 (Thermo Scientific, Waltham, MA, USA)
or mature miRNA miR-7/miR-148a (Applied Biosystems, Carlsbad, CA, USA) or inhibitor—miR-7
LNA/miR- 148a LNA (Exiqon, Vedbæk, Denmark) was added to a final concentration of 50 nM
together with 25 µL Turbofect transfection reagent (Fermentas, Leon-Rot, Germany) in 5 mL complete
growth medium and left to incubate for 15–20 min at room temperature (RT) before being added
drop-wise to the cells.
For growth analyses, 4× 104 cells (NCI-H727) or 1.5× 104 cells (CNDT2) were seeded in each well
into E-plates for use in the xCELLigence system (Roche/ACEA, San Diego, CA, USA) for proliferation
studies. The xCELLigence analyzer, which is an electronic cell sensor array technology, allows label-free
and real-time monitoring of cell proliferation. The presence of the cells on top of the electrodes will
affect the local ionic environment at the electrode/solution interface, leading to an increase in the
electrode impedance. The more cells that are attached to the electrodes, the larger the increases
in electrode impedance. For further details, see references [32,33]. The difference in cell number
seeding for growth assays is due to differences in size and proliferative rate between the two cell lines.
A series of analogue concentrations were used to find the optimal concentration for the actual growth
experiments. The analogues were added daily directly to the wells of the E-plates in complete growth
medium used for the normal passage of cells, without changing it for the duration of the entire growth
experiment. The concentrations of the analogues for growth experiments were BIM-23a760 10−7 M,
BIM-23023 10−7 M, BIM-23014 10−9 M and finally BIM-53097 10−9 M.
2.5. RNA Extraction
Total RNA was extracted using Trizol reagent (Life Technologies) according to the manufactures
specifications. The RNA concentration was measured on the NanoDrop (Thermo Fisher
Scientific, Wilmington, DE, USA) and the integrity determined using the Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA).
2.6. Somatostatin Receptors mRNA Quantification
The expressions of the SSTRs were quantitated as previously described [34] and normalized to
the expression of β-actin.
2.7. Laser Capture Microdissection
Tumor and normal cells from FFPE tissue, see tissue specifications above, were Laser Capture
Microdissected (LCM) using an Arcturus LCM system (ThermoFisher Scientific, Waltham, MA, USA).
10 µm sections of tissue were mounted on Pen Membrane slides (Applied Biosystems,
Foster City, CA, USA). Sections were stained with cresyl violet, using the LCM staining kit (Ambion,
Foster City, CA, USA/Life Technologies, Carlsbad, CA, USA) with cresyl violet according to the
manufacturer’s instructions. After tissue sections had been collected and transferred to the collection
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cap, the cap was immediately transferred and clicked on to an Eppendorf tube containing the 100 µL
of the Lysis Solution used in the first step of the RNAqueous®-Micro Kit (ThermoFisher Scientific).
The tube was inverted to ensure complete coverage of the dissected cells in the buffer. RNA isolation
was performed according to the manufacturer’s instructions.
2.8. qPCR of microRNA Expression
The expression of miR-7 and miR-148a was quantitated using TaqMan miRNA assay
(Applied Biosystems). Briefly, 100 ng of the total RNA was reversely transcribed into cDNA using gene
specific primers and the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) according
to the manufacturer’s protocol. Samples were run on the ABI PRISM 7900 HT Sequence Detection
System (Applied Biosystems). For normalization of the miRNA expression data the geometric mean of
hsa-miR-191 and RNU-44 were used [35]. Primer sequences are listed in Table 3.
Table 3. Primer sequences.
MiRNA Mature Sequence Product ID
miR-7 UGGAAGACUAGUGAUUUUGUUGU 000268
miR-148a UCAGUGCACUACAGAACUUUGU 000470
MiR-191 CAACGGAAUCCCAAAAGCAGCUG 002299
RNU-44 CCTGGATGATGATAGCAAATGCTG-ACTGAACATGAAGGTCTTAATTAGCTCTAACTGACT 001094
2.9. In Situ Hybridization
Formalin-fixed and paraffin-embedded (FFPE) tissue samples of carcinoid tumors
were obtained from the Department of Pathology (Rigshospitalet, Copenhagen, Denmark).
A double-DIG-labeled LNA-modified oligos miR-7 (Exiqon, Munich, Germany), probe sequence
5′-ACAACAAAATCACTAGTCTTCCA-3′, RNA-Tm 80 ◦C and double-DIG-labeled LNA-modified
oligos miR-148a (Exiqon), probe sequence 5′-ACAAAGTTCTGTAGTGCACTGA-3′, RNA-Tm 80 ◦C
were used for detection as described [36]. Probe concentration was 100 nM and slides were hybridized
at 50 ◦C. Sections were counterstained with Nuclear Fast Red. Pictures of representative areas of the
slides were taken with a Zeiss Axio Imager (Zeiss, Jena, Germany), original magnification × 20/10.
Cells with intense blue nuclear stain were scored as positive. The level of expression within a positive
cell was not scored. A LNA probe against snRNA U6 (Exiqon) was used as positive control and a
scramble probe (Exiqon) as negative control.
2.10. MicroRNA Microarray
For microarray analysis 1 µg of total RNA was labeled using the Flashtag RNA labeling kit
for Affymetrix (Genisphere LLC., Hatfield, PA, USA) according to the manufacturer’s instructions.
The labeled samples were hybridized to GeneChip miRNA Array (Affymetrix, Santa Clara, CA, USA).
The Affymetrix miRNA array assay miRNAs includes small nucleolar RNAs (snoRNAs) and small
Cajal Body specific RNAs (scaRNAs) in human. The 847 human miRNAs on the array are derived
from Sanger miRbase miRNA database V11. Four copies of each miRNA probe are distributed on
the array.
2.11. RNA Profiling
Arrays were washed and stained with phycoerytrin conjugated streptavidin (SAPE) using
the Affymetrix Fluidics Station® 450, and the arrays were scanned in the Affymetrix GeneArray®
3000 scanner to generate fluorescent images, as described in the Affymetrix Gene Chip® protocol.
To minimize batch variation, equal numbers of treatment groups were included in each batch.
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2.12. Data Analysis
Raw data files were imported into Affymetrix’s miRNA QC Tool (Affymetrix) and normalized
using the quantiles normalization and median Polish summarization following a background
correction that corrects for the GC content of the each particular probe. Log2 intensities of the
847 human miRNAs were imported into the Data Analysis software package Qlucore Omnics Explorer
v2.1. Principal Component Analysis (PCA) visualization of the clustering of samples using the genes
selected in the class comparison was performed using the build-in PCA tool in Qlucore Omnics
Explorer v2.1 (Qlucore AB, Lund, Sweden).
Class comparison analysis was performed using Students t-test. A multiple comparison test was
used for all three tissue-types and a two-group comparison was used for comparing AP versus NF.
The miRNA was defined as being differentially expressed between the compared groups if the p value
was less than 0.05 and the fold change above 1.5.
2.13. Statistical Analyses
Students’ unpaired t-test was used and differences with a p ≤ 0.05 were considered significant
and indicated by *. Unless otherwise stated results are given as median ± standard deviation (SD).
3. Results
3.1. Somatostatin and Dopamine Analogues Inhibit the Growth of a Carcinoid Cell Line NCI-H727
We first examined the expression of the SSTRs in four different carcinoid cell lines, HC45 and
CNDT2 (both intestinal) and the atypical NCI-H720 and typical NCI-H727 pulmonary cell lines,
in order to choose an optimal cell line as a model system for examining the effect of SSAs on miRNA
expression in NETs. All the carcinoid cell lines expressed SSTR subtypes 2 and 5 Figure 1A, and for
further analyses we selected two of the cell lines with highest SSTR2 mRNA level and each representing
common NET origins in lung (NCI-H727) and intestinal (CNDT2). Furthermore, the HC45 proved very
difficult to grow even after having been immortalized by retroviral transfection with a constitutive
active human Telomerase Reverse Transcriptase TERT expression vector and we discontinued using
this cell line. We have also previously shown that the CNDT2 and NCI-H727 cell lines are good model
systems when examining NETs [37] and proceed with these two cell lines as our model.
Figure 1. Carcinoid cell lines express all somatostatin receptors (SSRTs), and activation of both
SSTRs and DRD2 gives the most potent growth inhibition of a carcinoid cell line (A) All the four
examined carcinoid cell lines express SSTR subtype 2 and 5 when analyzed by qPCR (B) The growth of
NCI-H727 is inhibited by somatostatin, dopamine and the chimeric somatostatin-dopamine agonists.
The dopamine analogue BIM-53097 (blue) and the somatostatin analogues (SSAs) BIM—23023 (red)
were the weaker inhibitors of cell growth. The somatostatin agonist BIM-23014 (yellow) and the
chimeric somatostatin-dopamine compound BIM-23A760 (green) were the stronger inhibitors of
carcinoid cell growth. The control (black) is vehicle without agonist.
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Having shown that NCI-H727 cells expressed SSTR2- and five subtypes we examined the effect of
the SST and dopamine analogues on their growth. We found that all compounds inhibited the growth
of the carcinoid cell line (Figure 1B). The most potent inhibitor of proliferation was the combined SSTR
and dopamine receptor DR agonist BIM-23A760 (green) followed by the SSTR agonist BIM-23014
(yellow) and BIM-23023 (red). The least effective of the SSAs was the DR agonist BIM-53097 (blue)
Figure 1B.
3.2. Somatostatin Receptor Activation Primarily Induces microRNA Expression Changes
After having seen that SST analogues inhibit growth we treated NCI-H727 cells with the most
potent inhibitor—BIM-23A760—and compared the mRNA and miRNA profiles of treated cells with
that of untreated cells (Figure 2). PCA plots based on either mRNAs or miRNAs of cells treated with
SST analogue showed that PCA based miRNA expression profiles clearly separated controls from
treated cells. In contrast, PCA based mRNA profiles did not (Figure 2). Furthermore, when calculating
the number of transcripts changed and regulated by SST 24 h after treatment it is clear that treating
with SST regulates miRNAs to a higher degree than mRNAs (Figure 2).
Figure 2. The dual somatostatin-dopamine agonist BIM-23a760 induces greater changes in microRNA
(miRNA) than in messenger RNA (mRNA). Carcinoid NCI-H727 cells were treated with the dual
somatostatin-dopamine agonist BIM-23a760 for 24 h and the changes in mRNA and miRNA were
examined using microarray. Principal component analysis (PCA) of the changes in mRNA and miRNA
demonstrated that mRNA based PCA did not clearly separate the BIM-23a760 treated cells (shown in
red) from the control cells treated with vehicle without BIM-23a76 (shown in blue). In contrast a PCA
based on the changes in miRNA expression clearly separated the treated cells (shown in red) from the
untreated cells (shown in blue). This suggests that the miRNA changes induced by BIM-23a760 are
more specific than the changes in mRNA expression. This was also supported by the fact, that a higher
proportion of miRNA transcripts than of mRNA are changed by BIM-23a760 treatment.
3.3. Somatostatin Induces Distinct Receptor Based/Activated microRNA Expression Profiles and Particularly
Up-Regulates miR-7 and miR-148a
Having demonstrated that SST and dopamine analogues inhibited the growth of the carcinoid
cell line NCI-H727 and that activation of these receptors primarily affected miRNA expression,
we hypothesized that at least some of their growth inhibitory effects depended on receptor activation
and miRNA expression regulation. Also, after identifying the most potent inhibitor of growth among
the different SST analogues we expanded the study and examined all the different SST analogues’ effect
on miRNA expression by miRNA analysis of NCI-H727 cells treated with BIM-23A760, BIM-23014,
BIM-23023, BIM-53097 and with a control. A PCA of the miRNA expression profiles showed that,
depending on which analogue the cells were treated with, they could be separated into groups
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according to the analogue used and receptor(s) activated. In the first dimension the samples treated
with BIM-23a760 (SSTR/DRD2) and BIM-23014 (SSTR-only) analogues separated from the rest and in
the third dimension there was a difference in miRNA expression depending on receptor type activation
(Figure 3A).
Figure 3. PCA shows specific miRNA expression depending on receptor activation. (A) The unbiased
PCA separates the samples based on variation in the expression of miRNA in each sample. In the first
dimension samples treated with BIM-23014 (blue—SSTR agonist) and BIM- 23A760 (white—SSTR and
dopamine receptor D2 (DRD2) chimeric agonist) separated from the others. BIM-23023 (green—SSTR)
did not separate from the control (yellow). Also in the first dimension BIM-53097 (red—DRD2) did
not separate from the controls. However, in the third dimension the BIM-53097 (red—DRD2) treated
samples clearly separated from the controls. The percentage indicates how much of the total variation
is present in each dimension. In this experiment 22% of the total variation of miRNA expression is
found in the first dimension, 8% in the second and 7% in the third. The two most potent inhibitors of
growth BIM-23A760 and BIM-23014 group together, the DRD2 agonist and the least effective growth
inhibitor separates by itself. (B) The Venn diagram shows the miRNAs shared between the different
analogue treatments and that the number of miRNAs shared between BIM-23A760 (SSTR-DRD2) and
BIM-23014 (SSTR) are greater than BIM-53097 (DRD2). (C) On the right side of the map is the clustering
of treatment where DRD2 and controls separate from chimeric compound BIM-23A760 (SSTR-DRD2)
and BIM-23014 (SSTR). Furthermore it seems to separate controls and DRD2. Notice in the middle
of the control/DRD2 treatment, there is a small fraction of miRNA which seems to be controlled by
dopamine alone and different from the control group.
A Venn diagram shows the overlap between miRNA expression shared between the analogues and
analogue treatment. The results show that a higher number of miRNAs are affected and changed after
Genes 2018, 9, 337 9 of 17
treatments with BIM-23a760 and BIM-23014, which target SSTR either alone or in combination with
DRD2, compared to BIM-52097 which only targets DRD2. The highest degree of miRNA expressional
changes was induced by SSTR activation compared to selective DRD2 activation (Figure 3B). However,
a more specific miRNA expression change was observed in the small fraction of miRNAs changed
only in response to BIM-53097 and DRD2 receptor activation. Since BIM-23023 (SSTR) did not separate
from the control group in the PCA plot, it was excluded (Figure 3B). Based on the miRNA array results
we created a heat map to better visualize the changes in miRNA expression between the treatments
with the different compounds, again data with BIM-23023 (SSTR) being excluded (Figure 3C). We also
created a list of the most significantly down- or up regulated miRNAs from the two compounds which
showed the biggest inhibitory effect on cell proliferation BIM-23A760 (SSTR/DRD2), BIM-23014 (SSTR)
and the least effective growth inhibitor BIM-53097 (DRD2) (Table 4). From this list we chose to focus
on miR-7 and miR-148a.
Table 4. Up- and down-regulated miRNAs based on Somatostatin analogue (SSA) treatment.
miRNA Change
BIM-23014 BIM-23A760 BIM-53097
FC p-Value FC p-Value FC p-Value
miR-769-3p −2.8 0.001 −2.6 0.002 −1.1 NS
miR-663b −2.0 0.009 −2.5 0.001 −2.9 0.00
miR-663
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Figure 4. miR‐7 and miR‐148a are primarily expressed in neuroendocrine cells and inhibit the growth 
of  a  carcinoid  cell  line.  (A)  In  situ  hybridization  of  miR‐7  show  robust  expression  of  miR‐7 
specifically  located  to  the neuroendocrine cells. The expression of miR‐148a  is also predominantly 
seen in the neuroendocrine cells, although to a  lesser extent than miR‐7. (B) qPCR of  laser capture 
−2.0 0.007 −2.3 0.002 −3.3 0.00
miR-30b-star −2.0 0.001 −2.2 0.000 −1.3 NS
miR-297 −1.7 0.008 −2.0 .001 −1.7 0.0
iR-483-5p −1.9 0.003 −2.0 .002 −1.0 NS
miR-376c 2.1 0.000 2.0 0.000 −1.2 NS
Let-7f 1.8 0.001 2.1 0.000 −1.2 NS
miR-10a-star
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3.4. In Situ Hybridization and qPCR on Neuroendocrine Tumors and Neuroendocrine Tumor Laser Capture
Microdissected Tissue Confirms the Presence of miR-7 and miR-148a
To characterize the localization and to visualize the expression of miR-7 and miR-148a in NETs we
performed in situ hybridization n five NETs and found miR-7 expressed exclusively by the endocrine
cells, both tumor and ormal cells; miR-148a was also expressed pri arily by the endo rine cells
also both tumor and normal cells but to a lesser extent (Figure A). Expression analysis of LCM NET
tissue confirmed the up-regulation of p rticularly miR-7, t also shows the presence of miR-148a
(Figure 4B).
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Figure 4. miR-7 and miR-148a are primarily expressed in neuroendocrine cells and inhibit the growth
of a carcinoid cell line. (A) In situ hybridization of miR-7 show robust expression of miR-7 specifically
located to the neuroendocrine cells. The expression of miR-148a is also predominantly seen in the
neuroendocrine cells, although to a lesser extent than miR-7. (B) qPCR of laser capture micro dissected
cells confirmed that miR-7 is robustly expressed in NETs compared to normal mucosa. In contrast,
the expression of miR-148a is lower in NETs than in the normal mucosa that contains endocrine cells.
3.5. miR-7 and miR-148a Modulate the Growth of NCI-H727 and CNDT2 Carcinoid Cell Lines
Having demonstrated that SST analogues induced the expression of miR-7 and miR-148a and
that both these miRNAs are expressed in NETs, we examined how these miRNAs would affect
the growth of both the NCI-H727 and CNDT2 carcinoid cell lines by either over expressing or
inhibiting them. Both miR-7 and miR-148a significantly inhibit the growth of carcinoid cells in vitro
indicating that these miRNA could mediate some of the growth inhibitory effect induced by SST
analogues (Figure 5A,B). We subsequently blocked the effect of miR-7 and miR-148a by transfecting
LNA-inhibitors that increased the growth of both carcinoid cell lines (Figure 5C,D).
Figure 5. miR-7 and miR-148a regulates growth of the carcinoid cell lines NCI-H727 and CNDT2.
(A) and (B) Both miR-7 and miR-148a reduces cellular growth of the carcinoid cell lines NCI-H727
and CNDT2 where the highest inhibitory effect is caused by transfecting with miR-7. (C) and (D)
Inhibiting miR-7 and miR-148a by transfecting the carcinoid cell lines NCI-H727 and CNDT2 with
miRNA inhibitors alleviate growth repression and cause the cells to grow more than the controls.
* growth rates statistically significant compared to control.
Genes 2018, 9, 337 11 of 17
3.6. Somatostatin Modulates the Expression of the Let-7 Family
We have previously shown that the expression of several Let-7 family members is reduced during
NET carcinogenesis [37] and we therefore specifically examined how the SSTR and DRD2 analogues
affected the expression of the let-7 miRNA family. We found that the expression of 4 of the Let-7
members increased after treatment with SSTR analogues, the expression of one was slightly reduced
and the expression of 4 was unaffected (Table 5).
Table 5. Differentially regulated let-7 family members based on SSA treatment.
miRNA Change
BIM-23014 BIM-23A760 BIM-53097
FC p-Value FC p-Value FC p-Value
let-7a → 1.2 0.000 1.2 0.000 −1.0 NS
let-7b ↓ −1.4 0.000 −1.4 0.001 −1.0 NS
let-7c → −1.0 NS 1.0 NS −1.1 NS
let-7d → −1.0 NS 1.0 NS 1.1 NS
let-7e → −1.2 NS −1.1 NS 1.1 NS
let-7f ↑ 1.8 0.002 2.1 0.000 −1.2 NS
let-7g ↑ 1.7 0.001 1.9 0.000 −1.1 NS
let-7i ↑ 1.3 0.000 1.4 0.000 −1.1 NS
miR-98 ↑ 1.8 0.004 2.2 0.000 −1.1 NS
The alteration in the expression of the let-7 family of miRNAs in NIH-H727 cells after 24 h treatment with
somatostatin analogue BIM-23014, dopamine analogue BIM-53097 and the chimeric somatostatin-dopamine
analogue BIM-23a760. N = 4, NS—p-value not significant.
Thus, SST analogues had the ability to reintroduce the expression of the let-7 family and possibly
revert some of the pathways otherwise involved in NET carcinogenesis and malignancy.
4. Discussion
We have shown that in our NET model system SST analogue treatment primarily induces changes
in miRNA expression profiles in carcinoid cell lines. SST analogues are widely used to treat patients
with NETs, as the SST analogues both alleviate the carcinoid syndrome and inhibit growth of the
tumors [19,38–40]. Here we show that SST analogues inhibit the growth of two carcinoid cell lines
and that the inhibitory potential depends on the analogue used. This is in good concordance with
other studies that also show that SST analogues inhibit the growth of the NCI-H727 carcinoid cell
line [30,41] and the CNDT2 carcinoid cell line [42] and that a chimeric compound targeting SSTRs and
DRD2s has the most potent growth inhibitory effect [30,41,42]. The growth inhibitory effects of SST
analogues are mediated directly by binding of SST to the SSTRs, which leads to cell cycle arrest or
apoptosis and indirectly by the inhibition of growth factors and the suppression of oncogenic signal
transducing pathways. However, the molecular mechanisms linking neuroendocrine proliferation and
tumor progression are not yet fully understood. The PI3K/MAPK/mTOR pathway is known to play
an important role in NETs [43,44]. Already existing therapies used to treat patients with NETs consist
of agents targeting this specific signaling pathway [45–49]. SSTR2 has been shown to bind directly
to the p85 subunit of PI3K, which belongs to the class IA PI3Ks and is the class specifically involved
in promoting cell survival, growth and proliferation and the most important subclass involved in
human cancers [50,51]. SST analogue treatment of a pancreatic cell line can inhibit the binding between
SSTR2 and p85 which is critical for the down-regulation of PI3K activity and resulting decreased cell
survival [50].
We found miR-7 and miR-148a among the most up-regulated miRNAs after treatment with SST
analogues and increased expression of the let-7 family members, all of which have growth inhibitory
effects. miR-7 has been shown to be down-regulated in several cancers including colorectal cancer [52]
and gastric cancer [53] and to be endocrine specific [54], with evidence going both ways to whether or
not miR-7 acts as a tumor suppressor [55]. Here we demonstrated miR-7 to be highly present in NETs.
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Both miR-7 and SST targets the PI3K/MAPK/mTOR pathway underlining the significance for the
up-regulation of this specific miRNA by SST. In a study in lung cancers, including the carcinoid cell
line NCI-H727 showed miR-7 to directly target PI3KR3, the regulatory subunit of PI3K, and to reduce
the metastatic potential by reducing the effect of TLR9 signaling [56]. In hepatocellular carcinoma
miR-7 has been shown to directly target and repress PI3KCD an integral component of the PI3K
signaling pathway, thereby both inhibiting cellular growth, invasion and migration in vitro and more
importantly tumorigenesis and metastasis in vivo [57].
Another important aspect of the induction of miR-7 expression in cancer lies in the fact that miR-7,
through its inhibitory actions on central cancerous signaling pathways, can increase the sensitivity and
improve otherwise chemo-or radiotherapy resistant tumor cells [55]. SST mediates up- regulation of
miR-7 thereby increasing the cells sensitivity to the growth inhibitory actions of SST itself resulting in
a positive feed-forward loop.
miR-148a has been shown to be down-regulated in early gastric- [58], pancreatic- [59] and colon
cancer [60], as well as in breast cancer [61], and, when down-regulated, suggested as a biomarker
for the diagnosis and prognosis of gastrointestinal cancers [58,62,63]. Shivapurkar et al. showed that
a panel of six miRNAs including miR-148a could predict the risk of recurrence of colon cancer [60];
thus the up-regulation of miR-148a by SST analogue treatment might also be used as a biomarker in
NETs. We found miR-148a localized to endocrine cells and tumor tissue, all of which points towards
it being a specific and important miRNA in endocrine tumor formation and initiation. Our finding
that miR-148a has a growth inhibitory effect on carcinoid cell lines makes it an important miRNA to
up-regulate for SST analogues as it will give the SST analogues the ability to “pack that extra punch” in
stopping cell growth, and which is possibly why we see that SST analogue treatment primarily gives a
change in miRNA expression rather than mRNA expression.
SST itself attenuates Insulin Growth Factor 1 (IGF-1) signaling [64] and IGF-1 Receptor (IGF-1R) is
important in GEP-NET tumor growth factor biology [51]. Since miR-148a targets IGF-1, SST analogue
induced miR-148a expression could again lead to the interference with the PI3K signaling pathway by
the inhibition of growth factors like IGF-1 and its receptor IGF-1R, which frequently are overexpressed
in NETs [43,51]. Inhibition of IGF-1R signaling has been shown to decrease PI3K signaling and the
induction of cell cycle arrest and apoptosis [51]. miR-148a directly targets and down-regulates IGF-1R
in breast cancer and over-expression of miR-148a decreased phosphorylated Akt, a component of the
PI3K signaling pathway [61]. miR-7 also targets IGF-1R in a gastric cancer model with significant
influence on inhibiting the metastatic potential in this model [53]. However, while SSTR agonists have
been shown to have anti-tumor growth activity [30,41,42], IGF-1R inhibition proved to be ineffective
in treatment of NETs [65]. One explanation could be that IGF-1R inhibition only targets the receptor
activity but not directly the downstream signaling events. In contrast, SSTR activation and induction of
the miRNAs could potentially inhibit IGF-1R signaling at multiple levels and hence be more effective.
We have previously shown the let-7 family to be among the most down-regulated miRNA in NETs.
We also identified and that it targets HMGA2, BACH1 and MMP1 and reduce the expression of
these oncogenes all present in NETs [37]. Here we find that treatment with SST analogues modulates
the expression of the let-7 family and leads to the up-regulation of several family members and the
down-regulation of only one.
Recently, several reports have established the let-7 miRNAs as key players in metabolic pathways,
especially in the glucose metabolic pathway through the inhibition of IGF-1R, which is a key target
in the PI3K/mTOR signaling pathway [66]. Others have shown the let-7 family to directly target
and inhibit IGF-1 and IGF-1R, which harbors three let-7 binding sites in its 3’UTR. This leads to
the elimination of PI3K activation, and hence abrogates the signaling pathway leading towards cell
division, differentiation and survival. placing let-7 up-stream of IGF-1/IGF-1R with downstream
effects on the PI3K signaling cascade [67,68]. The positive modulation of the let-7 family by SST
analogues targets and inhibits the IGF-1/PI3K signaling pathway in addition to maybe inhibiting
glucose nutrient in aiding the rapid growth of the cancer cells. By this mechanism, they are targeted
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on both survival signaling as well as their supply of nutrients. In conclusion miR-7, miR-148a and the
let-7 family most up-regulated by SST have been shown to play a role in inhibiting the PI3K signaling
pathway at different levels reducing the cancer cell’s ability to escape and circumvent inhibition of a
single step. The fact that the miRNAs up-regulated by the SST analogues, the analogues themselves
and the already existing therapies all seem to target the same signaling pathway underlines the
importance of targeting this pathway when treating NETs.
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